Atlas Trials

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Clinical trial NCT04585815 · TERMINATED

Trial details

NCT number
NCT04585815
Sponsor
Pfizer
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Carcinoma, Non-Small-Cell Lung
Start date
2020-11-10
Primary completion
2023-05-17
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.